<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814175</url>
  </required_header>
  <id_info>
    <org_study_id>M14-496</org_study_id>
    <secondary_id>2016-000191-21</secondary_id>
    <nct_id>NCT02814175</nct_id>
  </id_info>
  <brief_title>A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country
      study in subjects with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 is designed
      to compare the achievement of minimal disease activity (MDA) between subjects randomized to
      either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the
      highest recommended or tolerable dose; Part 2 is to evaluate the maintenance or achievement
      of MDA on four different treatment regimens using adalimumab and/or MTX, with subject
      allocation based on the initial randomized treatment and achievement of MDA in Part 1, and
      with rescue treatment option.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving minimal disease activity</measure>
    <time_frame>At week 16</time_frame>
    <description>Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), Patient's assessment of pain visual analogue scale, Patient's global assessment of disease activity VAS, HAQ-DI, and tender entheseal points assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PASDAS from baseline</measure>
    <time_frame>Measured from Day 1 to week 16</time_frame>
    <description>Psoriatic Arthritis Disease Activity Score is a weighted disease activity measure developed specifically for psoriatic arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAPSA score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DAPSA is a psoriatic arthritis disease activity measure, calculated by summing swollen and tender joint counts, Patient's assessment of pain, Patients global assessment of disease activity, and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PsAID score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>PsAID is a validated patient self-reported tool to assess the impact of PsA on the patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving ACR 20/50/70 response</measure>
    <time_frame>At Week 16</time_frame>
    <description>ACR 20/50/70 response rate will be determined based on 20%, 50%, and 70% or greater improvement of Tender Joint Count and Swollen Joint Counts and greater than or equal to 3 of the 5 measures of Patient's assessment of pain, Patient's global assessment of disease activity, Physician's global assessment of disease activity, HAQ-DI, and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28-CRP score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DAS28 is a weighted measure of disease activity originally developed for RA, but is also used in PsA clinical trials. DAS28 includes tender and swollen joint counts, Patient's global assessment of disease activity, Patient's global assessment of arthritis and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PASI 75/90/100 response among subjects with BSA greater than or equal to 3%.</measure>
    <time_frame>At Week 16</time_frame>
    <description>Denotes greater than or equal to 75%/90%/100% improvement in PASI score. PASI provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAQ-DI score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>The HAQ-DI is a standardized measure of physical function in arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>SF-36 is a generic measure to assess patient's general health and well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DLQI is a measure of subject's quality of life related to skin disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leeds Enthesitis Index (LEI) from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tender dactylitic digit count from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>Hands and feet bilaterally will be assessed for the presence/absence of dactylitis and associated tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in minimal disease activity in Part 2 of the study</measure>
    <time_frame>At week 32</time_frame>
    <description>Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), Patient's assessment of pain visual analogue scale, Patient's global assessment of disease activity VAS, HAQ-DI, and tender entheseal points assessment.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab + MTX low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2/Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab + MTX low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab +MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab and/or MTX</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_label>Arm 1/Part 2</arm_group_label>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_label>Rescue Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate (MTX)</intervention_name>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_label>Arm 2/Part 1</arm_group_label>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_label>Arm 3/Part 2</arm_group_label>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_label>Rescue Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit
             and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria

          2. Not in MDA at the time of screening

          3. Has 3 or more tender and 3 or more swollen joints

          4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks and not more than 36
             weeks

        Exclusion Criteria:

          1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab
             or its excipients

          2. History of methotrexate intolerance/toxicity

          3. Medical conditions(s) precluding methotrexate dose increase above 15 mg

          4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of
             action biologic DMARD (bDMARD) or any systemic biologic agent in general
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Hojnik, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 158655</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 158655, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155178</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155178, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152088</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152088, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152089</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152089, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152087</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152087, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157815</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157815, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153146</name>
      <address>
        <city>Box Hill</city>
        <zip>3158</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153146, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153144</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153144, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153145</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153145, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153147</name>
      <address>
        <city>Liverpool</city>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153147, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153875</name>
      <address>
        <city>Parramatta</city>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153875, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152345</name>
      <address>
        <city>Porto Alegre</city>
        <zip>CEP 90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152345, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152344</name>
      <address>
        <city>Santo Andre</city>
        <zip>CEP 09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152344, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152658</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152658, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152657</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152657, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151938</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151938, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152575</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152575, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151937</name>
      <address>
        <city>Rimouski</city>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151937, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151939</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151939, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151753</name>
      <address>
        <city>Jihlava</city>
        <zip>586 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151753, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151754</name>
      <address>
        <city>Prague 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151754, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152229</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152229, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152231</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152231, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152013</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152013, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152011</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152011, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152012</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152012, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151987</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151987, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151988</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151988, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152957</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152957, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152091</name>
      <address>
        <city>San Juan</city>
        <zip>00909-3004</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152091, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152334</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152334, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151758</name>
      <address>
        <city>Badajoz</city>
        <zip>6010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151760</name>
      <address>
        <city>Badalona, Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151760, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151761</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151761, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152308</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152308, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151759</name>
      <address>
        <city>Sabadell, Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151759, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152767</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152767, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152769</name>
      <address>
        <city>Lancashire</city>
        <zip>PR2 8DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152769, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152766</name>
      <address>
        <city>Londonderry, Northern Ireland</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152766, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Qatar</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>June 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
